- Home
- SLGN vs TECH Comparison
SLGN vs TECH Comparison
Compare SLGN & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGN
- TECH
- Stock Information
- Founded
- SLGN 1987
- TECH 1976
- Country
- SLGN United States
- TECH United States
- Employees
- SLGN N/A
- TECH N/A
- Industry
- SLGN Containers/Packaging
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLGN Industrials
- TECH Health Care
- Exchange
- SLGN Nasdaq
- TECH Nasdaq
- Market Cap
- SLGN N/A
- TECH 8.0B
- IPO Year
- SLGN 1997
- TECH 1989
- Fundamental
- Price
- SLGN $49.31
- TECH $48.10
- Analyst Decision
- SLGN Strong Buy
- TECH Buy
- Analyst Count
- SLGN 9
- TECH 9
- Target Price
- SLGN $64.22
- TECH $81.25
- AVG Volume (30 Days)
- SLGN 977.1K
- TECH 2.2M
- Earning Date
- SLGN 04-30-2025
- TECH 05-07-2025
- Dividend Yield
- SLGN 1.61%
- TECH 0.63%
- EPS Growth
- SLGN N/A
- TECH N/A
- EPS
- SLGN 2.58
- TECH 0.98
- Revenue
- SLGN $5,854,694,000.00
- TECH $1,196,016,000.00
- Revenue This Year
- SLGN $11.91
- TECH $8.19
- Revenue Next Year
- SLGN $2.59
- TECH $8.85
- P/E Ratio
- SLGN $19.25
- TECH $52.13
- Revenue Growth
- SLGN N/A
- TECH 4.46
- 52 Week Low
- SLGN $41.14
- TECH $46.44
- 52 Week High
- SLGN $58.14
- TECH $85.57
- Technical
- Relative Strength Index (RSI)
- SLGN 48.17
- TECH 33.97
- Support Level
- SLGN $48.52
- TECH $46.44
- Resistance Level
- SLGN $49.76
- TECH $53.00
- Average True Range (ATR)
- SLGN 1.67
- TECH 3.30
- MACD
- SLGN 0.16
- TECH -0.27
- Stochastic Oscillator
- SLGN 68.04
- TECH 13.00
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.